Proteomics International Laboratories Ltd. announced the expansion of its executive team with the appointment of Vik Malik as its new Chief Commercialisation Officer. Medical Technologies commercialisation veteran Vik Malik will lead Proteomics International's commercial roll-out of the Company's innovative diagnostic products centred on the PromarkerD predictive test for diabetic kidney disease. Starting June 1, 2021, he will initially be based in the USA. Mr. Malik has an extensive network of clinical (KOL) and business professionals in the healthcare, medical device and diagnostics sectors, which will prove invaluable as Proteomics International ramps up the commercialisation of PromarkerD in the US and Europe.